Wound healing is a highly specialized dynamic process for the repair of damaged/injured tissues through an intricate mechanism. Any failure in the normal wound healing process results in abnormal scar formation, and a chronic state which is more susceptible to infections. Researchers from Monash University in Australia and Osaka University in Japan have demonstrated that the removal of a specific subtype of sensory neurons containing the Nav1.8+ ion channel significantly impairs skin wound repair and muscle regeneration following injury. Read More
A team from GC Cell Corp. reported preclinical data on GL-205, a novel allogeneic anti-CD5 CAR-NK being developed for the treatment of T-cell malignancies. GL-205 was developed using cord blood-derived NK cells that were genetically modified to express CD5-directed CAR and simultaneously produce IL-15 to support NK cell survival and proliferation. Read More
Sitryx Therapeutics Ltd. has nominated SYX-5219 as the first candidate from its proprietary pipeline to progress to regulatory nonclinical studies to support a clinical trial authorization (CTA). SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis. Read More
Cereno Scientific AB has submitted a clinical trial application (CTA) to the EMA seeking approval for a first-in-human, phase I study of CS-014, a novel histone deacetylase (HDAC) inhibitor drug candidate under development as an antithrombotic treatment. Read More
Cullgen (Shanghai) Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a DDB1- and CUL4-associated factor 1 (DCAF1) binding moiety covalently linked to target protein moiety (such as bromodomain-containing protein 4 [BRD4; HUNK1], cyclin-dependent kinase 4 [CDK4] and estrogen receptor α [ER-α; ESR1]) through a linker reported to be useful for the treatment of cancer. Read More
The overexpression of transferrin receptor 1 (TfR1) has been reported in several cancer types but is also expressed in normal cell types such as erythroblasts. On the other hand, epidermal growth factor receptor (EGFR) is highly expressed in epithelial carcinomas. Read More
The U.S. FDA has cleared Tr1x Inc.’s IND application for TRX-103 for the prevention of graft-vs.-host disease (GVHD) in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). Read More
Jnana Therapeutics Inc. has synthesized sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of amino acid metabolism disorders, amino acid transport disorders and metabolic and nutritional genetic disorders, among others. Read More
Scientists at East China Normal University, East China University of Science & Technology, Jinfeng Laboratory and Zhengzhou University have identified ribosomal protein S6 kinase α-6 (RPS6KA6; RSK-4) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Beijing Pharscin Innobio Co. Ltd. presented the discovery and preclinical characterization of a novel highly selective poly (ADP-ribose) polymerase 7 (PARP7) inhibitor, HSN-002066, being developed for the treatment of cancer. Read More
Scientists at H. Lundbeck A/S and Vernalis (R&D) Ltd. have divulged leucine-rich repeat kinase 2 (LRRK2; Dardarin) and LRRK2 G2019S mutant inhibitors reported to be useful for the treatment of Parkinson’s disease, Lewy body dementia and multiple system atrophy. Read More
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with poor prognosis and limited therapeutic options, and it accounts for 15%-20% of female invasive breast cancers. Read More
Researchers at Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have described 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome. Read More
